期刊文献+

某院64例替加环素临床应用回顾性分析

Retrospective Analysis of Clinical Application of Tigecycline in 64 Hospitalized Patients
下载PDF
导出
摘要 目的:对某院替加环素临床用药及管理情况进行评价。方法:应用回顾性研究方法,根据《替加环素临床应用评价细则》,对某院2018年替加环素的临床应用的有效性、安全性与合理性进行评价。结果:收集到相关病例共64份。替加环素用药前微生物送检率为98.4%,联合用药率为100%,临床应用评价得分(84.77±26.03)分;临床应用不合理43例(67.19%),主要表现为特殊使用级抗菌药物会诊不规范37例(57.81%),适应证不适宜5例(7.81%),用法用量不适宜10例(15.63%),使用抗菌药物前未送病原学检查1例(1.56%)。使用替加环素病例的临床有效率为56.25%;发生不良反应5例(7.81%)。替加环素给药剂量超说明书23例(35.94%)。结论:某院住院患者使用替加环素不合理率较高,主要表现为适应证不适宜、用法用量不适宜及特殊使用级抗菌药物处方与会诊管理不规范。替加环素合理用药水平有待提高。 Objective:To evaluate the clinical medication and management of tigecycline in a hospital.Methods:A retrospective study method was used to evaluate the rationality of the clinical application of tigecycline in the hospital in 2018 according to detailed rules for evaluation of clinical application of tigecycline.Results:A total of 64 cases were collected.The rate of microbial examination prior to the administration of tigecycline was 98.4%.The combined rate of tigecycline was 100%.The clinical application evaluation score of tigecycline was(84.77±26.03)points;There were 43 cases(67.19%)with unreasonable clinical application of tigecycline,the main manifestations were 37 cases(57.81%)with nonstandard consultation of special use antibiotics,5 cases(7.81%)with unsuitable indications,and 10 cases(15.63%)with inappropriate usage and dosage,and 1 case with no etiological examination before the use of antibiotics.The clinical effective rate of tigecycline was 56.25%;Adverse drug reactions occurred in 5 cases.23 cases(35.94%)of off-label drug use of tigecycline.Conclusion:The unreasonable rate of using tigecycline among inpatients in the hospital was high,which mainly reflected in inappropriate indications,inappropriate usage and dosage,and nonstandard prescription and consultation management of Specialized antibacterial drugs.The level of rational use of tigecycline shoud be improved.
作者 王小华 刘红 汪燕燕 王婷婷 吴佳俊 王卓芸 刘闪闪 夏泉 Wang Xiaohua;Liu Hong;Wang Yanyan;Wang Tingting;Wu Jiajun;Wang Zhuoyun;Liu Shanshan;Xia Quan(Department of Pharmacy,the First Affiliated Hospital of Anhui Medical University,The Grade 3 Pharmaceutical Chemistry Laboratory of State Administration of Traditional Chinese Medicine,Hefei 230000,China;Department of Pharmacy,Funan County People's Hospital;Chizhou Third People's Hospital;Department of Pharmacy,Anhui Children’s Hospital;Department of Pharmacy,Suzhou Municipal Hospital)
出处 《药物流行病学杂志》 CAS 2021年第7期461-466,共6页 Chinese Journal of Pharmacoepidemiology
基金 安徽省“十三五”临床重点专科建设项目(临床药学)(编号:卫科教秘[2017]529号)。
关键词 替加环素 合理用药 有效性 安全性 特殊使用级抗菌药物 Tigecycline Rational drug use Effectiveness Security Specialized antibacterial drugs
  • 相关文献

参考文献11

二级参考文献82

  • 1Tansarli GS,Rafailidis PI,Kapaskelis A,et al.Frequency of the off-label use of antibiotics in clinical practice:a systematic review[J].Expert Rev Anti Infect Ther,2012,10(12):1383-1392.
  • 2World Medical Association.World Medical Association Declaration of Helsinki:ethical principles for medical research involving human subjects[J].JAMA,2013,310 (20):2191-2194.
  • 3U.S.Food and Drug Administration.Highlights of prescribing information:TYGACIL?(tigecycline)for injection for intravenous use[EB/OL].[2014-09-22].http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021821s026s031lbl.pdf.
  • 4Giamarellou H.Multidrug-resistant Gram-negative bacteria:how to treat and for how long[J].Int J Antimicrob Agents,2010,36(2):S50.
  • 5Samonis G,Maraki S,Karageorgopoulos DE,et al.Synergy of fosfomycin with carbapenems,colistin,netilmicin,and tigecycline against multidrug-resistant Klebsiella pneumoniae,Escherichia coli,and Pseudomonas aeruginosa clinical isolates[J].Eur J Clin Microbiol Infect Dis,2012,31(5):695.
  • 6Morfin-Otero R,Dowzicky MJ.Changes in MIC within a global collection of Acinetobacter baumannii collected as part of the tigecycline evaluation and surveillance trial,2004 to 2009[J].Clin Ther,2012,34(1):101.
  • 7European Medicines Agency.Committee for medicinal products for human use,guideline on bioanalytical method validation[EB/OL].[2012-01-05].http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guidelin e/2011/08/WC500109686.pdf.
  • 8Ozcimen M,Sakarya Y,Ozcimen S,et al.Pharmacokinetics of intravenously administered tigecycline in eye compartments:an experimental study[J].Graefes Arch Clin Exp Ophthalmol,2014,252(12):1 993.
  • 9Hanberger H,Giske CG,Giamarellou H.When and how to cover for resistant gram-negative bacilli in severe sepsis and septic shock[J].Curr Infect Dis Rep,2011,13(5):416.
  • 10Garnacho-Montero J,Amaya-Villar R.Multiresistant Acinetobacter baumannii infections:epidemiology and management[J].Curr Opin Infec Dis,2010,23(4):332.

共引文献198

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部